Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant with moderate to severe HS for at least 1 year prior to baseline visit.
HS lesions present in at least two distinct anatomical areas.
Draining fistula count of ≤ 20 at Baseline visit.
Total abscess and inflammatory nodule (AN) count of ≥ 5 at Baseline visit.
Participants are required to use a daily antiseptic wash on their HS lesions.
Participant must have a history of inadequate response or intolerance to an adequate trial of oral antibiotics for treatment of HS.
You may not be if
Participant has a history of active skin disease other than HS that could interfere with the assessment of HS.
Participant has active tuberculosis (TB) or concurrent treatment for latent TB or evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection.
Participant has prior exposure to anti-interleukin-1 (anti-IL-1) treatment within 3 months or 5 half-lives, whichever is longer, prior to baseline.
Participant has received prescription topical therapies (including topical antibiotics) within 14 days prior to the Baseline visit.
Participant has received systemic non-biologic therapies that can also be used to treat HS within 4 weeks prior to the Baseline visit.
Participant has received any systemic (including oral) antibiotic treatment within 4 weeks prior to the Baseline visit.
Clareo Health | A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
